AstraZeneca, Schering to collaborate on anti-inflammatories

AstraZeneca and Schering have inked an agreement to collaborate on development and licensing of Selective Glucocorticoid Receptor Agonists (SEGRAs), potentially a new class of anti-inflammatory drugs. The two companies will jointly research and develop several SEGRAs that Schering has identified, through the end of Phase I clinical trials. After that, AstraZeneca will have an exclusive worldwide license to develop and market compounds for rheumatoid and respiratory diseases, while Schering will have the rights to all other uses of the drugs.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.